PERTH, Australia, 25th October 2017: Phylogica Limited (ASX:PYC) (Phylogica or the Company), developer of a leading intracellular drug delivery platform technology, is pleased to announce the establishment of and first appointments to a scientific advisory board (SAB).
The newly appointed SAB will serve as a strategic resource for Phylogica as the Company continues to develop its drug delivery platform technology, harnessing its ability to carry drug cargoes inside cells as new generation therapies for a range of diseases.
The first members of Phylogica’s SAB are:
Prof. Judy Lieberman
- Chair in Cellular and Molecular Medicine at Boston Children’s Hospital & Professor of Pediatrics, Harvard Medical School
Dr. Stephen Doberstein
- Senior Vice President and Chief Scientific Officer of Nektar Therapeutics
For further information please download PDF attached:
Download this document
